<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598571</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00027</org_study_id>
    <secondary_id>QBR112696</secondary_id>
    <nct_id>NCT01598571</nct_id>
  </id_info>
  <brief_title>Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose</brief_title>
  <official_title>A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib With Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Study in healthy males to assess bioavailability of single fostamatinib with iv micro tracer
      dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Fostamatinib with
      Respect to an Intravenous Micro Tracer Dose of [14C] R406 in Healthy Male Volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent of absolute bioavailability (F) of R406 after oral administration of fostamatinib.</measure>
    <time_frame>Up to 96 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity of [14C] R406 after an intravenous infusion of [14C]R406 in terms of AUC, AUC(0-t), Cmax, t1/2λz, MRT, CL, Vz.</measure>
    <time_frame>Up to 96 hours post dose</time_frame>
    <description>AUC-Area under the plasma concentration time curve; AUC(0-t)-Area under plasma concentration time curve from zero to time of the last measurable concentration; Cmax - max plasma concentration; t½ λz-Terminal half-life; MRT- Mean residence time; CL - Total body clearance; Vz - Volume of distribution during the terminal phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of a single oral dose of fostamatinib and a radiolabelled intravenous micro tracer dose of [14C] R406.</measure>
    <time_frame>0, 30min, 1h, 1h 30min, 1h 45min, 1h 50min, 1h 55min, 2, 2h 5min, 2h 10min, 2h 15min, 2h30min, 3, 3h 30min, 5h30min, 9h, 12h, 18h, 24h, 30h, 48h, 72h, 96h post-dose</time_frame>
    <description>PK Parameters: AUC, AUC (0-t), Cmax, t½ λz and MRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events.</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile in terms of vital signs (blood pressure and pulse), clinical laboratory tests, ECGs and physical examination findings.</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fostamatinib 50 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Fostamatinib 50 mg tablet</description>
    <arm_group_label>Fostamatinib 50 mg tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose</description>
    <arm_group_label>Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged 18 to 55 years (inclusive), with a weight of at least 50
             kg and a body mass index (BMI) between 18 and 30 kg/m2 (inclusive)

          -  Male volunteers willing to use barrier contraception ie, condoms with spermicide, from
             the first day of the investigational product administration until 3 months after the
             last administration of the investigational product

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  History or presence of GI, hepatic, or renal disease or any other condition known to
             interfere with absorption, distribution, metabolism, or excretion of drugs

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of drug

          -  Volunteers who smoke more than 5 cigarettes or the equivalent in tobacco per day

          -  Any clinically significant abnormalities in clinical chemistry, hematology or
             urinalysis results as judged by the Investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Layton, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Alderley Park</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharan Sidhu, MB CHB, BAO, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Clinical Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <last_update_submitted>August 21, 2012</last_update_submitted>
  <last_update_submitted_qc>August 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy male volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>fostamatinib</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>R406 plasma AUC and Cmax</keyword>
  <keyword>R406 plasma AUC0-t</keyword>
  <keyword>t1/2λz</keyword>
  <keyword>tmax</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

